{"id":"gemcitabine-and-erlotinib","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Rash"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1079742","moleculeType":"Small molecule","molecularWeight":"429.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine works by incorporating itself into DNA, causing DNA damage and inhibiting cancer cell growth. Erlotinib, on the other hand, binds to the EGFR, preventing the receptor from activating downstream signaling pathways that promote cell proliferation and survival.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:37.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT01660971","phase":"PHASE1","title":"Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-30","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7","enrollment":19},{"nctId":"NCT00878163","phase":"PHASE1","title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03-31","conditions":"Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":55},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT01204372","phase":"PHASE2","title":"Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2010-06","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":63},{"nctId":"NCT01013649","phase":"PHASE3","title":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-05","conditions":"Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm","enrollment":546},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT00885066","phase":"PHASE1","title":"Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2008-05","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01555489","phase":"PHASE2","title":"Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2011-10","conditions":"Stage IV Pancreatic Cancer","enrollment":11},{"nctId":"NCT00954525","phase":"PHASE1","title":"Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-07","conditions":"Metastatic Pancreatic Cancer","enrollment":14},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT00446225","phase":"PHASE3","title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT01010945","phase":"PHASE1","title":"Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"OSI Pharmaceuticals","startDate":"2010-02-03","conditions":"Advanced Pancreatic Cancer","enrollment":19},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT02098954","phase":"PHASE2","title":"Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-07-01","conditions":"Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation","enrollment":40},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03110484","phase":"PHASE2","title":"Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-07-09","conditions":"Biliary Tract Cancer","enrollment":44},{"nctId":"NCT00883480","phase":"NA","title":"Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2005-06","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT00617708","phase":"PHASE1, PHASE2","title":"S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03","conditions":"Stage IV Pancreatic Cancer","enrollment":134},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT01683422","phase":"NA","title":"Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Loma Linda University","startDate":"2013-01-02","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT01210911","phase":"PHASE2","title":"Metformin Combined With Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2010-08","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT01178411","phase":"PHASE1, PHASE2","title":"An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2010-08-31","conditions":"Advanced Solid Tumors","enrollment":60},{"nctId":"NCT02154737","phase":"PHASE1","title":"Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Tony Reid, M.D., Ph.D.","startDate":"2013-07","conditions":"Pancreatic Cancer","enrollment":24},{"nctId":"NCT00376948","phase":"PHASE2","title":"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-05","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00769483","phase":"PHASE1, PHASE2","title":"MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-11-13","conditions":"Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":81},{"nctId":"NCT00313560","phase":"PHASE2","title":"ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-03-16","conditions":"Pancreatic Cancer","enrollment":48},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT03403049","phase":"PHASE1","title":"Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-04-01","conditions":"Pancreatic Cancer, Cancer","enrollment":14},{"nctId":"NCT00026338","phase":"PHASE3","title":"Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2001-10-29","conditions":"Pancreatic Cancer","enrollment":569},{"nctId":"NCT02117024","phase":"PHASE2","title":"A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2014-07","conditions":"Non Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT00728000","phase":"PHASE2","title":"Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma","status":"WITHDRAWN","sponsor":"University of Cincinnati","startDate":"2008-08","conditions":"Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT00733746","phase":"PHASE2","title":"Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":123},{"nctId":"NCT01505530","phase":"PHASE2","title":"A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT02737228","phase":"PHASE1, PHASE2","title":"Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CrystalGenomics, Inc.","startDate":"2016-03","conditions":"Pancreatic Neoplasms","enrollment":24},{"nctId":"NCT00354549","phase":"PHASE2","title":"Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-01","conditions":"Lung Cancer","enrollment":104},{"nctId":"NCT00603915","phase":"PHASE2","title":"A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-06","conditions":"Nasopharyngeal Cancer","enrollment":20},{"nctId":"NCT01376310","phase":"PHASE2","title":"GSK1120212 Rollover Study","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11-02","conditions":"Cancer","enrollment":159},{"nctId":"NCT01284335","phase":"PHASE1","title":"A Safety Study in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2008-07","conditions":"Advanced Solid Tumors","enrollment":234},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT01407822","phase":"PHASE2, PHASE3","title":"Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2011-12-05","conditions":"Non-small Cell Lung Cancer","enrollment":72},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT03628521","phase":"PHASE1","title":"First-line Combination Treatment Based on Anlotinib","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2018-07-20","conditions":"Lung Cancer, Advanced Stage","enrollment":80},{"nctId":"NCT01782690","phase":"","title":"An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-03-31","conditions":"Pancreatic Cancer","enrollment":338},{"nctId":"NCT00832637","phase":"PHASE2","title":"Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2007-08","conditions":"Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct","enrollment":33},{"nctId":"NCT02004262","phase":"PHASE2","title":"Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting","status":"COMPLETED","sponsor":"Aduro Biotech, Inc.","startDate":"2014-02-05","conditions":"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","enrollment":303},{"nctId":"NCT01389440","phase":"PHASE2","title":"Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-05","conditions":"Pancreatic Adenocarcinoma","enrollment":24},{"nctId":"NCT01395758","phase":"PHASE2","title":"Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2011-07","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT00365144","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-02","conditions":"Pancreatic Cancer","enrollment":36},{"nctId":"NCT00810719","phase":"PHASE2","title":"Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT00033241","phase":"PHASE1","title":"Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors","status":"COMPLETED","sponsor":"OSI Pharmaceuticals","startDate":"2001-07-23","conditions":"Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01531712","phase":"PHASE2","title":"Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable","status":"TERMINATED","sponsor":"Institut Català d'Oncologia","startDate":"2011-02-10","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT01693419","phase":"PHASE2","title":"S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2011-08","conditions":"Pancreas Neoplasms","enrollment":37},{"nctId":"NCT01303029","phase":"PHASE2","title":"Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2011-02","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT01729481","phase":"PHASE2","title":"Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":150},{"nctId":"NCT02178397","phase":"PHASE3","title":"A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR","status":"TERMINATED","sponsor":"Centre Francois Baclesse","startDate":"2014-06","conditions":"NSCLC Patients With EGFR Activating Mutation","enrollment":6},{"nctId":"NCT00987766","phase":"PHASE1","title":"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2009-11","conditions":"Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer","enrollment":28},{"nctId":"NCT00841035","phase":"PHASE2","title":"7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2009-02","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT00366457","phase":"PHASE2","title":"Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-08","conditions":"Pancreatic Cancer, Adenocarcinoma of the Pancreas","enrollment":32},{"nctId":"NCT00283244","phase":"PHASE2","title":"Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-03","conditions":"Lung Cancer","enrollment":147},{"nctId":"NCT00550836","phase":"PHASE2","title":"Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":104},{"nctId":"NCT02694536","phase":"PHASE3","title":"A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08-01","conditions":"Pancreatic Cancer","enrollment":80},{"nctId":"NCT00761345","phase":"PHASE1","title":"Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2008-09","conditions":"Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer","enrollment":27},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00059852","phase":"PHASE2","title":"Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-06","conditions":"Breast Cancer","enrollment":61},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT00260364","phase":"PHASE1, PHASE2","title":"Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2005-11","conditions":"Pancreatic Cancer","enrollment":44},{"nctId":"NCT00336700","phase":"PHASE2","title":"A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer","status":"TERMINATED","sponsor":"Herbert J. Zeh, III MD, FACS","startDate":"2006-06","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT00642733","phase":"PHASE4","title":"A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT00705874","phase":"PHASE1","title":"Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Progen Pharmaceuticals","startDate":"2006-05","conditions":"Cancer","enrollment":172},{"nctId":"NCT00696696","phase":"PHASE2","title":"Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2007-09","conditions":"Pancreatic Cancer","enrollment":45},{"nctId":"NCT00701558","phase":"PHASE2","title":"A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":20},{"nctId":"NCT00766636","phase":"PHASE2","title":"Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-09","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT00518011","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":17},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT00349219","phase":"PHASE3","title":"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2006-12","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":760},{"nctId":"NCT02000531","phase":"PHASE4","title":"Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00883779","phase":"PHASE3","title":"A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":451},{"nctId":"NCT00634725","phase":"PHASE3","title":"Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-02","conditions":"Pancreatic Cancer","enrollment":820},{"nctId":"NCT00461708","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Pancreatic Cancer","enrollment":153},{"nctId":"NCT01454180","phase":"PHASE2","title":"Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2011-10","conditions":"Advanced Pancreatic Carcinoma","enrollment":31},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00940875","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Non-Small Cell Lung Cancer","enrollment":54},{"nctId":"NCT01342965","phase":"PHASE3","title":"A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Non-Small Cell Lung Cancer","enrollment":217},{"nctId":"NCT00652366","phase":"PHASE2","title":"A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Pancreatic Cancer","enrollment":467},{"nctId":"NCT01998919","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Non-Small Cell Lung Cancer","enrollment":154},{"nctId":"NCT00531960","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT01214720","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pancreatic Cancer","enrollment":607},{"nctId":"NCT01181245","phase":"PHASE1","title":"A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2008-12","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":50},{"nctId":"NCT00091026","phase":"PHASE2","title":"Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-07","conditions":"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer","enrollment":143},{"nctId":"NCT01505413","phase":"PHASE2","title":"Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2011-01","conditions":"Pancreatic Cancer","enrollment":33},{"nctId":"NCT00636883","phase":"PHASE2","title":"Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer","status":"TERMINATED","sponsor":"National Guard Health Affairs","startDate":"2008-01","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT00298415","phase":"PHASE3","title":"Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2006-03","conditions":"NSCLC","enrollment":451},{"nctId":"NCT00418704","phase":"","title":"Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2006-05","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT00419042","phase":"","title":"Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2006-07","conditions":"Non Small Cell Lung Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemcitabine and Tarceva"],"phase":"phase_2","status":"active","brandName":"Gemcitabine and Erlotinib","genericName":"Gemcitabine and Erlotinib","companyName":"Grupo Espanol Multidisciplinario del Cancer Digestivo","companyId":"grupo-espanol-multidisciplinario-del-cancer-digestivo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Used for Pancreatic cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}